Naoki Mita1, Takuji Iwashita2, Shinya Uemura1, Yuhei Iwasa1, Katsuhisa Toda3, Tsuyoshi Mukai4, Tatsuhiko Miyazaki5, Ichiro Yasuda6, Masahito Shimizu1. 1. First Department of Internal Medicine, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan. 2. First Department of Internal Medicine, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan. takuji@w7.dion.ne.jp. 3. Department of Gastroenterology, Chuno Kosei Hospital, Gifu, Japan. 4. Department of Gastroenterology, Gifu Municipal Hospital, Gifu, Japan. 5. Department of Pathology, Gifu University Hospital, Gifu, Japan. 6. Third Department of Internal Medicine, University of Toyama Hospital, Toyama, Japan.
Abstract
BACKGROUND: Recently, a novel 22-gauge needle with three symmetric needle points and crown-shaped cutting heels, known as a Franseen needle, has been developed for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB). AIM: To assess the histological material acquisition rate and histological diagnostic capability of the 22-gauge Franseen needle (AC22) during EUS-FNB for solid lesions. METHODS: This study was designed as an open-label, multicenter, prospective, single-arm pilot study of EUS-FNB using AC22 for the diagnosis of solid lesions. Three passes of FNB using AC22 were performed for all lesions. The primary endpoints were the histological material acquisition rate and histological diagnostic capability. The secondary endpoints were the technical success rate, quality of histological samples, number of passes for diagnosis, and safety. RESULTS: Between September 2017 and May 2018, 75 patients were enrolled. The final diagnoses were malignancy in 65 and benign in 10. Three passes of FNB were technically successful in all patients. The sensitivity, specificity, and accuracy for the malignancy of histological analyses were 92.3% (60/65), 100% (10/10), and 93.3% (70/75), respectively, for the first pass and 95.4% (62/65), 100% (10/10), and 96% (72/75), respectively, for combined three passes. The diagnostic yield plateaued after the second pass. Sufficient tissue samples for histological interpretation were obtained in 96% (72/75) and 100% (75/75) patients for the single pass and combined three passes, respectively. Two patients (2.7%) developed mild pancreatitis as an adverse event. CONCLUSION: EUS-FNB using AC22 showed high histological diagnostic capability with the high first pass yield. CLINICAL TRIALS REGISTRY: UMIN Clinical Trials Registry (UMIN ID: UMIN000036641).
BACKGROUND: Recently, a novel 22-gauge needle with three symmetric needle points and crown-shaped cutting heels, known as a Franseen needle, has been developed for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB). AIM: To assess the histological material acquisition rate and histological diagnostic capability of the 22-gauge Franseen needle (AC22) during EUS-FNB for solid lesions. METHODS: This study was designed as an open-label, multicenter, prospective, single-arm pilot study of EUS-FNB using AC22 for the diagnosis of solid lesions. Three passes of FNB using AC22 were performed for all lesions. The primary endpoints were the histological material acquisition rate and histological diagnostic capability. The secondary endpoints were the technical success rate, quality of histological samples, number of passes for diagnosis, and safety. RESULTS: Between September 2017 and May 2018, 75 patients were enrolled. The final diagnoses were malignancy in 65 and benign in 10. Three passes of FNB were technically successful in all patients. The sensitivity, specificity, and accuracy for the malignancy of histological analyses were 92.3% (60/65), 100% (10/10), and 93.3% (70/75), respectively, for the first pass and 95.4% (62/65), 100% (10/10), and 96% (72/75), respectively, for combined three passes. The diagnostic yield plateaued after the second pass. Sufficient tissue samples for histological interpretation were obtained in 96% (72/75) and 100% (75/75) patients for the single pass and combined three passes, respectively. Two patients (2.7%) developed mild pancreatitis as an adverse event. CONCLUSION: EUS-FNB using AC22 showed high histological diagnostic capability with the high first pass yield. CLINICAL TRIALS REGISTRY: UMIN Clinical Trials Registry (UMIN ID: UMIN000036641).
Entities:
Keywords:
Endoscopic ultrasound-guided fine needle aspiration; Endoscopic ultrasound-guided fine needle biopsy; Franseen; Histology; Tissue acquisition
Authors: Julia Kim LeBlanc; Donato Ciaccia; Mohammed T Al-Assi; Kevin McGrath; Tom Imperiale; Liang-Che Tao; Steve Vallery; John DeWitt; Stuart Sherman; Edith Collins Journal: Gastrointest Endosc Date: 2004-04 Impact factor: 9.427
Authors: Peter B Cotton; Glenn M Eisen; Lars Aabakken; Todd H Baron; Matt M Hutter; Brian C Jacobson; Klaus Mergener; Albert Nemcek; Bret T Petersen; John L Petrini; Irving M Pike; Linda Rabeneck; Joseph Romagnuolo; John J Vargo Journal: Gastrointest Endosc Date: 2010-03 Impact factor: 9.427
Authors: Tae Jun Song; Ji Hoon Kim; Sang Soo Lee; Jun Bum Eum; Sung Hoon Moon; Do Hyun Park; Dong Wan Seo; Sung Koo Lee; Se Jin Jang; Sung Cheol Yun; Myung-Hwan Kim Journal: Am J Gastroenterol Date: 2010-03-09 Impact factor: 10.864
Authors: Ji Young Bang; Shantel Hebert-Magee; Udayakumar Navaneethan; Muhammad K Hasan; Robert Hawes; Shyam Varadarajulu Journal: Gut Date: 2017-10-07 Impact factor: 23.059
Authors: Rintaro Hashimoto; David P Lee; Jason B Samarasena; Vishal S Chandan; Wenchang Guo; John G Lee; Kenneth J Chang Journal: Dig Dis Sci Date: 2020-06-17 Impact factor: 3.199